Limited Offer
Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part B
- 1st Edition, Volume 366 - January 24, 2022
- Editors: Niccolo Bartalucci, Lorenzo Galluzzi
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 8 9 9 4 1 - 3
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 9 9 4 2 - 0
Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part B, Volume 366 in the International Review of Cell and Molecular Biology series, highlights new advances in t… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteCellular and Molecular Aspects of Myeloproliferative Neoplasms - Part B, Volume 366 in the International Review of Cell and Molecular Biology series, highlights new advances in the field, with this new volume presenting interesting chapters written by an international board of authors. Sections cover Genetic and Sex predisposition to MPN, Transcriptional configurations of Myeloproliferative Neoplasms, Inhibitors and therapeutic targets of MPN, Mutational landscape of blast-phase myeloproliferative neoplasm (MPN-BP) and antecedent MPN, and Lessons from Mouse model of MPN, Lab tests for MPN.
- Publishes only invited review articles on selected topics
- Authored by established and active cell and molecular biologists from international sources
- Offers a wide range of perspectives on specific subjects
Academic, government and industrial sectors
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives
- Acknowledgments
- Conflict of Interest
- References
- Chapter One: The roles of sex and genetics in the MPN
- Abstract
- Key Points
- 1: Introduction
- 2: Sex as a factor in MPN epidemiology
- 3: Biologic basis of sex differences in somatic mutation burden
- 4: Genetic predisposition to CH and the MPN
- 5: Heritable risk factors for CH and MPN
- 6: Inflammation as a risk for CH and MPN
- 7: Mutation burden and clinical risk
- 8: Conclusion
- Funding
- Conflicts of interest
- References
- Chapter Two: Transcriptional configurations of myeloproliferative neoplasms
- Abstract
- 1: Introduction
- 2: Studies on the bulk transcriptome of MPN patients
- 3: From bulk to single cell transcriptomic sequencing of MPN patients
- 4: Analysis of splicing abnormalities with RNA-seq
- 5: Analysis of fusion genes in MPN and post-MPN AML patients
- 6: Concluding remarks and future directions
- References
- Chapter Three: Targets in MPNs and potential therapeutics
- Abstract
- 1: Introduction
- 2: JAK2 mutations
- 3: TPOR/MPL inhibition strategies
- 4: CALR mutations
- 5: Other targeted therapies
- 6: Conclusion
- Acknowledgments
- References
- Chapter Four: Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN
- Abstract
- 1: Introduction
- 2: Importance of activated JAK/STAT signaling and driver mutations
- 3: Driver mutations and beyond in MPN and leukemic transformation
- 4: Conclusions
- Acknowledgments
- Disclosures
- References
- Chapter Five: Lessons from mouse models of MPN
- Abstract
- 1: “Of mice and Men”
- 2: MPN driver mutations via the JAK2/STAT signaling pathway
- 3: Modeling MPN in mice—An up-to-date description
- 4: Lessons from MPN mouse modeling: What it means for patients
- 5: Conclusions and remarks
- Acknowledgments
- References
- Chapter Six: Lab tests for MPN
- Abstract
- 1: Philadelphia chromosome (Ph) positive myeloproliferative neoplasms (Ph + MPNs)
- 2: Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs)
- 3: Source of sample and DNA template for genetic testing in MPNs
- 4: Conclusions
- References
- No. of pages: 240
- Language: English
- Edition: 1
- Volume: 366
- Published: January 24, 2022
- Imprint: Academic Press
- Hardback ISBN: 9780323899413
- eBook ISBN: 9780323899420
NB
Niccolo Bartalucci
Niccolo Bartalucci practices in Florence, Italy. Dr. Bartalucci is highly rated in 6 conditions, according to our data. His top areas of expertise are Essential Thrombocythemia, Myelofibrosis, Polycythemia Vera, and Splenomegaly. His clinical research consists of co-authoring 34 peer reviewed articles in the past 15 years.
Affiliations and expertise
Department of Experimental and Clinical Medicine, University of Florence, ItalyLG
Lorenzo Galluzzi
Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.
Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:
OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.
Affiliations and expertise
Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USA